Key result
AUC-guided dosing and monitoring for vancomycin is recommended over trough-only control to minimize acute kidney injury, which increases when daily AUC exceeds 600 mg × hr/L.
Why the study?
Revised vancomycin consensus guidelines recommended AUC-guided dosing and monitoring for serious invasive MRSA infections to minimize vancomycin-associated acute kidney injury while maintaining effectiveness.
Does AUC-guided dosing and monitoring of vancomycin reduce vancomycin-associated acute kidney injury compared to trough-only control in patients with serious MRSA infections?
Does AUC-guided dosing and monitoring of vancomycin reduce vancomycin-associated acute kidney injury compared to trough-only control in patients with serious MRSA infections?
AUC-guided dosing and monitoring of vancomycin is recommended over trough-only monitoring to minimize the risk of acute kidney injury while maintaining therapeutic efficacy in serious MRSA infections.
May support AUC-guided vancomycin dosing to limit AKI; hypothesis-generating pending randomized confirmation.
The revised vancomycin consensus guidelines recommended area under the curve (AUC)-guided dosing/monitoring for patients with serious invasive methicillin-resistant Staphylococcus aureus (MRSA) infections as a measure to minimize vancomycin-associated acute kidney injury (VA-AKI) while maintaining similar effectiveness. Data indicate that the intensity of vancomycin exposure drives VA-AKI risk. Troughs of 15-20 mg/L will ensure an AUC ≥400 mg × hr/L but most patients will have daily AUCs >600. VA-AKI increases as a function of AUC, especially when >600. In addition to minimizing VA-AKI risk while maintaining similar efficacy, AUC-guided dosing/monitoring is a more precise way to conduct therapeutic drug monitoring for vancomycin relative to trough-only control.
No takes yet. Share an insight, caveat, or question.
Lodise et al. (2020) conducted a review in serious invasive methicillin-resistant Staphylococcus aureus (MRSA) infections. Area under the curve (AUC)-guided dosing and monitoring vs. trough-only control was evaluated on vancomycin-associated acute kidney injury (VA-AKI). AUC-guided dosing and monitoring for vancomycin is recommended over trough-only control to minimize acute kidney injury, which increases when daily AUC exceeds 600 mg × hr/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: